A Status Check Of The Alzheimer’s Trial Landscape
Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.
You may also be interested in...
'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
The fourth annual CARE Awards returned to Boston, Massachusetts, 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.